Merit Medical reports positive WAVE trial results

SOUTH JORDAN, Utah - Merit Medical Systems, Inc. (NASDAQ: MMSI), a prominent healthcare technology company valued at $5.65 billion, announced the successful 12-month outcomes of its WAVE trial at the Charing Cross Symposium in London on April 23, 2025. The trial evaluated the WRAPSODY CIE device in patients with arteriovenous grafts (AVGs). According to InvestingPro data, Merit Medical maintains a strong financial health score, with analysts projecting continued profitability this year.

The WRAPSODY CIE’s Target Lesion Primary Patency (TLPP) at six months was 81.4%, surpassing the performance goal by 21.4 percentage points. Safety outcomes were also favorable, with 95.4% of patients free from adverse events, exceeding the 89.0% safety performance goal (p=0.016). At the 12-month mark, the TLPP stood at 60.2%.

The WAVE trial’s single-arm cohort included 112 AVG patients. Access circuit primary patency (ACPP) rates were recorded at 69.2% at six months and 36.2% at 12 months. These results highlight the potential of the WRAPSODY CIE device to improve care for patients with failing AVGs, offering an alternative to limited existing options.

Dr. Robert G. Jones, Co-Principal Investigator of the WAVE trial, expressed enthusiasm about the findings and their implications for patient care. Fred P. Lampropoulos, Merit’s Chairman and CEO, echoed this sentiment, noting the company’s commitment to enhancing patient outcomes.

The WAVE trial’s 12-month randomized arm findings, along with six-month efficacy results, were previously presented and published, showcasing the WRAPSODY CIE’s consistent performance.

Merit Medical, founded in 1987, specializes in disposable medical devices for various procedures, with a global reach in sales and clinical support. The company employs around 7,300 people worldwide.

The WRAPSODY CIE is commercially available in Brazil, the European Union, and the United States. For further details on the WAVE study, refer to the clinical trials registry. This article is based on a press release statement from Merit Medical Systems, Inc.

In other recent news, Merit Medical Systems, Inc. reported impressive financial results for the first quarter of 2025, exceeding analysts’ expectations. The company achieved an earnings per share (EPS) of $0.86, surpassing the forecasted $0.75, and reported revenue of $355.4 million, slightly above the anticipated $352.52 million. Notably, the cardiovascular segment sales increased by 9%, while the endoscopy segment saw a significant 64% rise. However, despite these positive outcomes, Merit Medical’s management revised its EPS guidance downward due to tariff impacts, although the 2025 revenue forecast remained unchanged. Needham analysts responded by lowering the company’s stock target to $100 from $116, while maintaining a Buy rating. They expressed confidence in Merit Medical’s operational performance, noting potential relief if China tariff rates decrease. The company also reported a year-over-year gross margin increase of 250 basis points and an operating margin improvement of 230 basis points. Free cash flow for the first quarter was $20 million, slightly down from $25 million in the previous year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.